Christophe Deben
Advancing Tumor Organoid Drug Screening
In our recent webinar, we delved into the transformative potential of live-cell imaging for advancing organoid drug screening. A key...
top of page
Christophe Deben
Jan 231 min read
Auranofin Repurposing for Lung and Pancreatic Cancer: Low CA12 Expression as a Marker of Sensitivity in Patient-Derived Organoids, with Potentiated Efficacy by AKT Inhibition.
This study embarked on an ambitious journey, utilizing twenty 384-well microplates, exploring 11 drug synergy combinations, and analyzing...
300
Christophe Deben
Jan 232 min read
Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer
In this translational study, we explore pancreatic ductal adenocarcinoma (PDAC) and its inherent treatment resistance, emphasizing the...
90
Christophe Deben
Jan 232 min read
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
In this publication, we introduce an innovative drug screening methodology using patient-derived tumor organoids. This paper focuses on...
260
Christophe Deben
Jan 232 min read
OrBITS: label-free and time-lapse monitoring of patient derivedorganoids for advanced drug screening
In our original manuscript, we delve into the foundational work behind the development of the OrBITS label-free organoid detection...
280
Christophe Deben
Jan 123 min read
Unlocking the Potential of Tumor Organoid Screening: Choosing Between Widefield and Confocal Live-Cell Imaging
Introduction Live-cell imaging techniques are emerging as an invaluable tool for drug development, offering unprecedented insights into...
810
Christophe Deben
Nov 30, 20234 min read
The Evolution of Preclinical Models in Drug Screening: From 2D Cell Lines to Patient-Derived Models
Introduction: Preclinical models are the cornerstone of drug screening and development, playing a pivotal role in the advancement of...
840
bottom of page